lifitegrast Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
integrin antagonists 5174 1025967-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lifitegrast
  • SAR 1118-023
  • SAR 1118
  • SAR-1118
  • xiidra
a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
  • Molecular weight: 615.48
  • Formula: C29H24Cl2N2O7S
  • CLOGP: 2.28
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 133.99
  • ALOGS: -5.03
  • ROTB: 7

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
July 11, 2016 FDA SHIRE DEV LLC

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 4707.11 171.44 536 1168 93 4637195
Instillation site reaction 3975.53 171.44 447 1257 7 4637281
Vision blurred 2073.85 171.44 428 1276 24375 4612913
Dysgeusia 1046.19 171.44 225 1479 14594 4622694
Instillation site irritation 891.09 171.44 103 1601 16 4637272
Instillation site erythema 868.41 171.44 101 1603 22 4637266
Instillation site pruritus 811.91 171.44 93 1611 6 4637282
Instillation site lacrimation 684.48 171.44 78 1626 1 4637287
Eye irritation 555.56 171.44 112 1592 5102 4632186
Instillation site discharge 402.82 171.44 46 1658 1 4637287
Product quality issue 377.56 171.44 106 1598 19993 4617295
Instillation site swelling 356.96 171.44 41 1663 3 4637285
Lacrimation increased 345.64 171.44 74 1630 4479 4632809
Drug ineffective 284.88 171.44 158 1546 185903 4451385
Product container issue 283.77 171.44 51 1653 1222 4636066
Instillation site discomfort 269.13 171.44 31 1673 3 4637285
Ocular hyperaemia 251.90 171.44 61 1643 6379 4630909
Inappropriate schedule of product administration 237.04 171.44 76 1628 22294 4614994
Eye pain 226.13 171.44 58 1646 7659 4629629
Eye discharge 216.22 171.44 41 1663 1324 4635964
Visual impairment 177.12 171.44 59 1645 19401 4617887
Instillation site inflammation 175.42 171.44 20 1684 0 4637288

Pharmacologic Action:

SourceCodeDescription
ATC S01XA25 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
CHEBI has role CHEBI:35472 anti-inflammatory drug
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
FDA EPC N0000192701 Lymphocyte Function-Associated Antigen-1 Antagonist
FDA MoA N0000192700 Lymphocyte Function-Associated Antigen-1 Antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Tear film insufficiency indication 46152009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.42 acidic
pKa2 12.3 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 10124000 Nov. 5, 2024 TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 7745460 Nov. 5, 2024 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 7790743 Nov. 5, 2024 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8592450 May 17, 2026 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8367701 April 15, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 9447077 April 15, 2029 TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8168655 May 9, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC July 11, 2021 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-L/beta-2 Adhesion ANTAGONIST IC50 8.05 SCIENTIFIC LITERATURE DRUG LABEL
Intercellular adhesion molecule 1 Unclassified IC50 8.53 CHEMBL

External reference:

IDSource
D10374 KEGG_DRUG
038E5L962W UNII
9584 INN_ID
720489009 SNOMEDCT_US
763569006 SNOMEDCT_US
1801820 RXNORM
016935 NDDF
4035938 VANDF
31873 MMSL
11965427 PUBCHEM_CID
CHEBI:133023 CHEBI
DB11611 DRUGBANK_ID
CHEMBL2048028 ChEMBL_ID
CHEMBL2048409 ChEMBL_ID
7533 IUPHAR_LIGAND_ID
C575157 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 54092-606 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 15 sections